Home / Stocks / SARTF

SARTF (Life Sciences Tools & Services) Stock Valuation & Fair Value Significantly overvalued

SARTF (Life Sciences Tools & Services) trades at a blended P/E of 38.8, about 16% above its historical normal valuation, with a forward growth estimate of 19.0% and a PEG of 2.04. Analysts' one-year estimates have been hit 27% of the time.

No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation, forecast return and analyst accuracy only. Ratings that cite business quality require one.

DATA AS OF 2026-09-21
Blended P/E
38.8
Normal P/E
33.5
PEG
2.04
Fwd growth
19.0%
Div yield
0.4%
RSI (14)
97.5
Overbought

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-09-19.

Blended P/E and rating by weekBlended P/E moved from 38.8 to 38.8 between 2026-09-19 and 2026-09-21, against a normal P/E of 33.5, with 0 rating changes over 2 recorded weeks.2026-09-19: P/E 38.8, Significantly overvalued (recalculated)2026-09-21: P/E 38.8, Significantly overvalued34.036.038.0Sep 19Sep 20Sep 21Normal P/E 33.5
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Ratings recorded live since 2026-09-21. Earlier points apply today's valuation rules to the metrics tickerseer archived that week.

WeekBlended P/EPremium to normal P/ERating
2026-09-19P/E 38.8+16%Significantly overvalued
2026-09-21P/E 38.8+16%Significantly overvalued ← now

Frequently asked questions

Is SARTF overvalued?

At a blended P/E of 38.8 versus its historical normal P/E of 33.5, SARTF trades about 16% above its typical valuation, with a PEG of 2.04 on 19.0% forward growth. tickerseer currently rates it significantly overvalued.

What is SARTF's fair value and PEG?

SARTF trades at a blended P/E of 38.8 against a historical normal P/E of 33.5, a PEG of 2.04, and a forward growth estimate of 19.0%.

Has tickerseer's rating of SARTF changed?

tickerseer's rating has been significantly overvalued since 2026-09-19.

Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track SARTF free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.